Skip to content
Join our community and subscribe to our free weekly newsletter
Subscribe
Toggle Navigation
Latest News
Articles
Live Talks
Trials Update
Prevention & Risk Factors
Science-Backed Dementia Prevention
Alzheimer’s Genetics & Risk Factors
Menopause
Long COVID
Dementias
Alzheimer’s Disease
Vascular Dementia
Frontotemporal Dementia (FTD)
Lewy Body Dementia
Traumatic Brain Injury & CTE
Brain Disorders
Mild Cognitive Impairment (MCI)
Parkinson’s Disease
Getting Diagnosed
Diagnosis
Journey to Diagnosis
Genetic Testing
Alzheimer’s Biomarkers
Diversity and Dementia
Caregivers
Caregiver Voices
Learning Guides
Search for:
Search for:
Simon Spichak, MSc
Beyond the Hype: What Does the Lecanemab News Mean for People with Alzheimer’s?
Cuba Has an Experimental Alzheimer’s Drug In Human Trials
A New Kind of Alzheimer’s Drug, AD101, Makes Its Way
Meet Eli Lilly’s New Phase 3 Alzheimer’s Drug, Remternetug
Why Some Researchers Are Calling Alzheimer’s “Type 3 Diabetes”
First-Ever Drug for Alzheimer’s Agitation, Brexpiprazole, Nears Finish Line
CTAD: Lecanemab On Track to File for FDA Approval In Early 2023
Natural Supplements for Alzheimer’s Disease
Why Chris Hemsworth Is Worried About Alzheimer’s: Meet the APOE4 Gene
Alzheimer’s Drugs 101: How Do Cholinesterase Inhibitors Work?
Pills to Patches: Exploring New Formats for Alzheimer’s Treatments
Foods to Reverse Dementia? Here’s What the Science Says
What Parts of the Brain Does Alzheimer’s Affect?
A Death During an Alzheimer’s Drug Trial Ignites Safety Concerns
SHMOOSE Clues: Scientists Discover Influential New Alzheimer’s Gene
Previous
21
22
23
Next
Page load link
Go to Top